GlassScriptPhysician profile
Attiya Haroon
NPI 1891286688
$3,080.21
in general payments reported to CMS, 2019-2025
22 companies · $1,288 in 2025
The $1,288 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $255 · 2023: $711 · 2024: $827 · 2025: $1,288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,726 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,726.25 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $736.53 | 2022-2025 | Opzelura, Opzelura, Iclusig |
| E.R. Squibb & Sons, L.L.C. | $369.94 | 2022-2024 | Sotyktu |
| Janssen Biotech, INC. | $368.68 | 2023-2025 | Tremfya |
| Abbvie INC. | $349.31 | 2023-2025 | |
| Leo Pharma INC. | $261.13 | 2023-2025 | Adbry, Spevigo |
| Gilead Sciences, INC. | $125.35 | 2025 | Yeztugo |
| Novartis Pharmaceuticals Corporation | $124.25 | 2023-2025 | |
| Amgen INC. | $113.80 | 2025 | Otezla |
| Regeneron Healthcare Solutions, INC. | $111.62 | 2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $110.17 | 2023 | Farxiga |
| Ucb, INC. | $108.98 | 2023-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $58.75 | 2022-2023 | Winlevi |
| Surgenex LLC | $35.65 | 2025 | Ardeograft, Surmatrix, Pellograft |
| Dermavant Sciences, INC. | $32.95 | 2024 | Vtama |
| Galderma Laboratories, L.P. | $31.78 | 2023-2024 | Epsolay |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $31.04 | 2023 | |
| Verrica Pharmaceuticals INC. | $23.02 | 2024 | Ycanth |
| Lnhc, INC | $20.95 | 2025 | Zelsuvmi |
| Biofrontera INC. | $18.43 | 2025 | |
| Arcutis Biotherapeutics, INC. | $16.73 | 2024 | Zoryve |
| Botanix Sb INC | $16.04 | 2025 | Sofdra |
| Organon LLC | $15.11 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Attiya Haroon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.